Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01881867 · ClinicalTrials.gov registry record · Phase 2

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 2
Development phase
54
Enrollment target
16
Study locations

NCT01881867 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 54 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (30% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01881867, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
54 participants
Enrollment target
16
Study locations

Study Summary

This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with castration-resistant prostate cancer that has spread to other areas of the body or has not responded to at least one type of treatment. Biological therapies, such as glycosylated recombinant human interleukin-7, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. It is not yet known whether glycosylated recombinant human interleukin-7 works better with or without vaccine therapy in treating prostate cancer.

Conditions Studied

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer Castration Levels of Testosterone

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Glycosylated Recombinant Human Interleukin-7

Study Locations (16)

California

  • UC San Diego Moores Cancer Center - La Jolla
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • UCSF Medical Center-Mount Zion - San Francisco
  • UCSF Medical Center-Mission Bay - San Francisco

Washington

  • Fred Hutchinson Cancer Research Center - Seattle
  • Seattle Cancer Care Alliance - Seattle
  • University of Washington Medical Center - Seattle

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New Hampshire

  • Dartmouth Hitchcock Medical Center - Lebanon

New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2013-09-10
Est. Completion 2018-01-02
Phase Phase 2

Sponsor

Fred Hutchinson Cancer Center

483 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01881867

The ClinicalTrials.gov registry entry for NCT01881867 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (30% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01881867 reports 16 study locations spanning 11 distinct geographic areas - top geographies include California, Washington, Georgia.

Frequently Asked Questions

What is clinical trial NCT01881867 about?

NCT01881867 is a clinical study titled "CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer". This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with castration-resistant prostate cancer that has spread to other areas of the body or has not responded to at least one type of treatment. Biologic...

What is the current status of trial NCT01881867?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2013-09-10. Estimated completion is 2018-01-02.

What conditions does trial NCT01881867 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer, Castration Levels of Testosterone.

What interventions are being tested in trial NCT01881867?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Glycosylated Recombinant Human Interleukin-7 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01881867?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01881867 being conducted?

This trial has 16 study locations across California, Georgia, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Castration-Resistant Prostate Carcinoma

All registered trials for this condition

Metastatic Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.